This trial is testing whether a certain type of drug can help improve vitiligo, a condition where patches of skin lose their color. The trial is double-blind, meaning neither the participants nor the researchers will know who is receiving the experimental treatment until the trial is over.
1 Primary · 4 Secondary · Reporting Duration: Baseline (pre-treatment) and at 3 months (12 weeks) and 6 months (24 weeks)
64 Total Participants · 6 Treatment Groups
Primary Treatment: NBUVB phototherapy · Has Placebo Group · Phase 2
Age 18 - 75 · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|University of Colorado Anschutz - Clinical and Translational Research Centers||100.0%|
|Did not meet criteria||50.0%|